TMX3

Across TCGA pan-cancer cohorts, TMX3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMX3 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMX3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMX3 expression acts as an unfavorable survival marker.

LUAD, CCRCC, and LSCC are the cancer types where TMX3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.218	0.792	.003	28	view →
CCRCC	OS	Median	III,IV	0.202	0.985	.007	15	view →
LSCC	DFS	Median	II,III,IV	0.862	0.965	.030	4	view →
UCEC	DFS	Tertile	All	0.817	0.974	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMX3–LUAD (DFS)

Open the LUAD breakdown →